Drugmaker Granules says it will tighten internal oversight following a warning from the US FDA. The company, one of the world’s biggest paracetamol makers and a key active pharmaceutical ingredients player, earns a large share of revenue from the United States—making compliance scrutiny especially consequential for future supply and sales.
Granules India says it will strengthen its manufacturing oversight after a US FDA warning related to documentation practices and contamination concerns. The company plans to digitize workflows and automate record management to improve data accuracy and compliance. Granules is positioning the reforms as proactive steps to address regulatory pressure while maintaining product quality across its facilities.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
